These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Endocrine ophthalmopathy and radioiodine therapy. Karlsson FA Acta Oncol; 2006; 45(8):1046-50. PubMed ID: 17118837 [TBL] [Abstract][Full Text] [Related]
8. Soluble CD40 and its ligand CD154 in patients with Graves' ophthalmopathy during combined therapy with corticosteroids and teleradiotherapy. Myśliwiec J; Waligórski D; Nikołajuk A; Górska M Adv Med Sci; 2007; 52():104-8. PubMed ID: 18217399 [TBL] [Abstract][Full Text] [Related]
9. Susceptibility genes in Graves' ophthalmopathy: searching for a needle in a haystack? Bednarczuk T; Gopinath B; Ploski R; Wall JR Clin Endocrinol (Oxf); 2007 Jul; 67(1):3-19. PubMed ID: 17521325 [TBL] [Abstract][Full Text] [Related]
10. Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy. Eckstein AK; Lösch C; Glowacka D; Schott M; Mann K; Esser J; Morgenthaler NG Br J Ophthalmol; 2009 Aug; 93(8):1052-6. PubMed ID: 19221109 [TBL] [Abstract][Full Text] [Related]
11. Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Eckstein AK; Lax H; Lösch C; Glowacka D; Plicht M; Mann K; Esser J; Morgenthaler NG Clin Endocrinol (Oxf); 2007 Oct; 67(4):607-12. PubMed ID: 17880407 [TBL] [Abstract][Full Text] [Related]
12. Cambridge Ophthalmological Symposium 2018: introduction and reflections on the day. Ludgate M Eye (Lond); 2019 Feb; 33(2):169-173. PubMed ID: 30568255 [TBL] [Abstract][Full Text] [Related]
13. Eye muscle force development in thyroid-associated ophthalmopathy in different stages of disease. Tian S; Bolzani R; Benassi M; Lennerstrand G Acta Ophthalmol Scand; 2007 Jun; 85(4):431-7. PubMed ID: 17559468 [TBL] [Abstract][Full Text] [Related]
15. Association of CTLA-4 gene polymorphism with Graves' disease and ophthalmopathy in Iranian patients. Esteghamati A; Khalilzadeh O; Mobarra Z; Anvari M; Tahvildari M; Amiri HM; Rashidi A; Solgi G; Parivar K; Nikbin B; Amirzargar A Eur J Intern Med; 2009 Jul; 20(4):424-8. PubMed ID: 19524188 [TBL] [Abstract][Full Text] [Related]
16. Induction of stimulating thyrotropin receptor antibodies after radioiodine therapy for toxic multinodular goitre and Graves' disease measured with a novel bioassay. Hovens GC; Heemstra KA; Buiting AM; Stokkel MP; Karperien M; Ballieux BE; Pereira AM; Romijn JA; Smit JW Nucl Med Commun; 2007 Feb; 28(2):123-7. PubMed ID: 17198353 [TBL] [Abstract][Full Text] [Related]
17. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy. Molnár I Autoimmunity; 2007 Feb; 40(1):31-7. PubMed ID: 17364495 [TBL] [Abstract][Full Text] [Related]
18. Effect on intraocular pressure of extraocular muscle surgery for thyroid-associated ophthalmopathy. Gomi CF; Yates B; Kikkawa DO; Levi L; Weinreb RN; Granet DB Am J Ophthalmol; 2007 Nov; 144(5):654-657. PubMed ID: 17870046 [TBL] [Abstract][Full Text] [Related]
19. The thyroid-stimulating hormone receptor: impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimerization, cleavage, and signaling. Latif R; Morshed SA; Zaidi M; Davies TF Endocrinol Metab Clin North Am; 2009 Jun; 38(2):319-41, viii. PubMed ID: 19328414 [TBL] [Abstract][Full Text] [Related]
20. Comparison of a solid phase human- versus porcine- thyrotropin receptor-based immunoassay for the measurement of thyrotropin receptor antibodies in patients with thyroid diseases. Hermsen D; Liu C; Domberg J; Graeber C; Feldkamp J; Duan Y; Xu K; Liu C; Mao X; Scherbaum WA; Schott M Exp Clin Endocrinol Diabetes; 2008 Sep; 116 Suppl 1():S59-63. PubMed ID: 18777457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]